Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Packaging Signal-mediated Assembly - How Viruses Outsmart Their Hosts.

Journal of molecular biology·2026

Same author

Cryo-EM of human rhinovirus reveals capsid-RNA duplex interactions that provide insights into virus assembly and genome uncoating.

Communications biology·2024

Same author

Visualizing Viral RNA Packaging Signals in Action.

Journal of molecular biology·2024

Same author

Molecular frustration: a hypothesis for regulation of viral infections.

Trends in microbiology·2023

Same author

Is intestinal transport dysfunctional in COVID-19-related diarrhea?

American journal of physiology. Gastrointestinal and liver physiology·2023

Same author

A bovine antibody possessing an ultralong complementarity-determining region CDRH3 targets a highly conserved epitope in sarbecovirus spike proteins.

The Journal of biological chemistry·2022

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Development of aptamer therapeutics.

David H J Bunka¹, Olga Platonova, Peter G Stockley

¹Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK.

Current Opinion in Pharmacology

|July 20, 2010

Summary

Aptamer research is rapidly expanding, with a focus on developing aptamer therapeutics. This review highlights the isolation and development processes for aptamer drugs, including Pegaptanib (Macugen), the first approved human aptamer therapeutic.

More Related Videos

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis

Published on: January 7, 2017

Related Experiment Videos

Last Updated: Jun 10, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis

Published on: January 7, 2017

Area of Science:

Biotechnology
Molecular Biology
Drug Development

Background:

Aptamer research has seen significant growth, with numerous publications exploring diverse applications.
Aptamers are increasingly recognized for their potential as diagnostic and therapeutic agents.
The development of aptamer-based therapeutics is a rapidly advancing field.

Purpose of the Study:

To review the processes involved in isolating and developing aptamers for therapeutic use.
To provide examples of aptamer therapeutics, including the first approved human therapeutic, Pegaptanib (Macugen).
To discuss the current status of aptamer therapeutics in preclinical and clinical trials.

Main Methods:

Literature review focusing on aptamer isolation and development strategies.
Analysis of specific case studies, including Pegaptanib (Macugen).
Overview of aptamer therapeutics in various stages of clinical development.

Main Results:

The field of aptamer research is experiencing exponential growth.
Aptamers demonstrate broad applicability, from research tools to clinical therapeutics.
Pegaptanib (Macugen) represents a successful example of an approved aptamer therapeutic.

Conclusions:

Aptamer development offers a promising avenue for novel therapeutic strategies.
Continued research and clinical trials are essential for advancing aptamer therapeutics.
The successful approval of Pegaptanib underscores the therapeutic potential of aptamers.